Neumora Therapeutics, Inc. 10-K Cybersecurity GRC - 2025-03-03

Page last updated on March 3, 2025

Neumora Therapeutics, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2025-03-03 07:32:49 EST.

Filings

10-K filed on 2025-03-03

Neumora Therapeutics, Inc. filed a 10-K at 2025-03-03 07:32:49 EST
Accession Number: 0000950170-25-030401

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

ITEM 1C. Cybersecurity. Management of Cybersecurity Risks and Cybersecurity Strategy We have developed and implemented a cybersecurity program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business. Our cybersecurity program shares common methodologies, reporting channels and governance processes as the risk management programs of other departments within our company, including the legal, compliance, strategic, operational, and financial departments. Key elements of our cybersecurity program includes but are not limited to the following: - risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information; - a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents; - the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes; - cybersecurity awareness training of our employees, including incident response personnel, and senior management; - a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and - ad hoc internal review of the cybersecurity practices of key service providers, suppliers, and vendors who have access to our critical systems and information based on our assessment of their criticality to our operations and respective risk profile. We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled “Risk Factors- Our information technology systems, or those used by our third-party research institution collaborators, CROs, CMOs, or other contractors or consultants, may fail or suffer cyberattacks or security breaches.” Cybersecurity Governance Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the “Committee”) oversight of cybersecurity risks, including oversight of management’s implementation of our cybersecurity program. The Committee receives annual reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors also receives briefings from management on our cybersecurity program. Board members receive presentations on cybersecurity topics from our Senior Director of Infrastructure and Cybersecurity, internal security staff or external experts as part of the board of directors’ continuing education on topics that impact public companies. Our management team, including our Senior Director of Infrastructure and Cybersecurity (20 years of cybersecurity risk management experience) and Chief Information Officer (five years of cybersecurity risk management experience), is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our management team’s experience includes demonstrated expertise in cybersecurity, life sciences, and security industry certifications such as Certified Information Security Manager (CISM) and Certified Information Systems Security Professional (CISSP). Our management team takes steps to stay informed about and monitor supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.


Company Information

NameNeumora Therapeutics, Inc.
CIK0001885522
SIC DescriptionBiological Products, (No Diagnostic Substances)
TickerNMRA - Nasdaq
Website
CategoryNon-accelerated filer
Smaller reporting company
Emerging growth company
Fiscal Year EndDecember 30